Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 TriTAC-XR
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
CD19 TriTAC-XR (HPN601) is an investigational, extended-release trispecific T-cell engager (TriTAC) prodrug developed by Harpoon Therapeutics (now part of Merck & Co.) for the treatment of CD19-positive hematologic malignancies. It is engineered using the TriTAC-XR platform, which incorporates a peptide mask and a protease-cleavable linker at the N-terminus of the trispecific construct. The molecule binds to CD19 on B cells, CD3ε on T cells, and human serum albumin for extended half-life. As a prodrug, it remains inactive in systemic circulation until the mask is removed by proteases, allowing for a controlled release of the active T-cell engager. This mechanism is intended to reduce the peak drug concentration (Cmax) and minimize the risk of cytokine release syndrome (CRS) while maintaining therapeutic efficacy.
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CD19 TriTAC-XR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 TriTAC-XR.